Using Utilities

REFERENCES

1. ↵
   1. Fries JF,
   2. Spitz P,
   3. Kraines RG,
   4. Holman HR

   . Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137–45.

   OpenUrlCrossRefPubMed
2. ↵
   1. Meenan RF,
   2. Mason JH,
   3. Anderson JJ,
   4. Guccione AA,
   5. Kazis LE

   . AIMS2. The content and properties of a revised and expanded Arthritis Impact Measurement Scales health status questionnaire. Arthritis Rheum 1992;35:1–10.

   OpenUrlCrossRefPubMed
3. ↵
   1. Ware JE Jr,
   2. Sherbourne CD

   . The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473–83.

   OpenUrlCrossRefPubMed
4. ↵
   1. Hurst NP,
   2. Kind P,
   3. Ruta D,
   4. Hunter M,
   5. Stubbings A

   . Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 1997;36:551–9.

   OpenUrlAbstract/FREE Full Text
5. ↵
   1. Garratt A

   . Patient reported outcome measures in trials. BMJ 2009;338:a2597.

   OpenUrlFREE Full Text
6. ↵
   1. Linde L,
   2. Sørensen J,
   3. Østergaard M,
   4. Hørslev-Petersen K,
   5. Hetland ML

   . Does clinical remission lead to normalization of EQ-5D in patients with RA and is the selection of remission criteria important?. J Rheumatol 2010;37:285–90.

   OpenUrlAbstract/FREE Full Text
7. ↵
   1. Horsman J,
   2. Furlong W,
   3. Feeny D,
   4. Torrance G

   . The Health Utilities Index (HUI): concepts, measurement properties and applications. Health Qual Life Outcomes 2003;1:54.

   OpenUrlCrossRefPubMed
8. ↵
   1. Garratt A,
   2. Schmidt L,
   3. Mackintosh A,
   4. Fitzpatrick R

   . Quality of life measurement: bibliographic study of patient assessed health outcome measures. BMJ 2002;324:1417.

   OpenUrlAbstract/FREE Full Text
9. ↵
   1. Boonen A,
   2. Maetzel A,
   3. Drummond M,
   4. Suarez-Almazor M,
   5. Harrison M,
   6. Welch V,
   7. et al.

   The OMERACT initiative. Towards a reference approach to derive QALY for economic evaluations in rheumatology. J Rheumatol 2009;36:2045–9.

   OpenUrlAbstract/FREE Full Text
10. ↵
    1. Bansback N,
    2. Marra C,
    3. Tsuchiya A,
    4. Anis A,
    5. Guh D,
    6. Hammond T,
    7. et al.

    Using the Health Assessment Questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis. Arthritis Rheum 2007;57:963–71.

    OpenUrlCrossRefPubMed
11. ↵
    1. Prevoo ML,
    2. van ’t Hof MA,
    3. Kuper HH,
    4. van Leeuwen MA,
    5. van de Putte LB,
    6. van Riel PL

    . Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.

    OpenUrlCrossRefPubMed
12. ↵
    1. Aletaha D,
    2. Smolen JS

    . The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. Best Pract Res Clin Rheumatol 2007;21:663–75.

    OpenUrlCrossRefPubMed
13. ↵
    1. Uhlig T,
    2. Loge JH,
    3. Kristiansen IS,
    4. Kvien TK

    . Quantification of reduced health-related quality of life in patients with rheumatoid arthritis compared to the general population. J Rheumatol 2007;34:1241–7.

    OpenUrlAbstract/FREE Full Text
14. ↵
    1. Kind P,
    2. Macran S

    . A five-level version of the EQ-5D. Value Health 2004;7:637–56.

    OpenUrlCrossRefPubMed
15. ↵
    1. Pickard AS,
    2. De Leon MC,
    3. Kohlmann T,
    4. Cella D,
    5. Rosenbloom S

    . Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients. Med Care 2007;45:259–63.

    OpenUrlCrossRefPubMed
16. ↵
    1. Janssen MF,
    2. Birnie E,
    3. Haagsma JA,
    4. Bonsel GJ

    . Comparing the standard EQ-5D three-level system with a five-level version. Value Health 2008;11:275–84.

    OpenUrlCrossRefPubMed
17. ↵
    1. Maetzel A,
    2. Strand V,
    3. Tugwell P,
    4. Wells G,
    5. Bombardier C

    . Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Rheum 2002;47:655–61.

    OpenUrlCrossRefPubMed